PICO Portalanswers from OpenAlex & ORCID
René González
ResearcherPublications, citations & collaboration network
René González is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does René González have?
PICO Portalindexed works
René González has 372 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does René González have?
PICO Portalcitation count
René González has 60,403 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of René González?
PICO Portalh-index
René González has an h-index of 71 in OpenAlex.
What is the i10-index of René González?
PICO Portali10-index
René González has an i10-index of 170 in OpenAlex.
What is the ORCID of René González?
PICO Portalorcid
The ORCID for René González is on the source record.
What is the OpenAlex record for René González?
PICO Portalopenalex
The OpenAlex for René González is on the source record.
What are the most-cited papers on René González?
PICO Portalmost cited works
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su, Amaya Virós, Carla Milagre, Kerstin Trunzer, Gideon Bollag, Olivia Spleiss, Jorge S. Reis‐Filho, Xiangju Kong, Richard C. Koya, Keith T. Flaherty, Paul B. Chapman, Min Jung Kim, Robert Hayward, Matthew J. Martin, Hong Yang, Qiongqing Wang, Holly Hilton, Julie S. Hang, Johannes Noé, Maryou Lambros, Felipe C. Geyer, Nathalie Dhomen, Ion Niculescu‐Duvaz, Alfonso Zambon, Dan Niculescu‐Duvaz, Natasha Preece, Lídia Robert, Nicholas Otte, Stephen Mok, Damien Kee, Yan Ma, Chao Zhang, Gaston Habets, Elizabeth A. Burton, Bernice H. Wong, Hoa Nguyen, Mark Kockx, Luc Andries, Brian Lestini, K. B. Nolop, Richard J. Lee, Andrew K. Joe, James L. Troy, René González, Thomas E. Hutson, Igor Puzanov, Bartosz Chmielowski, Caroline J. Springer, Grant A. McArthur, Jeffrey A. Sosman, Roger S. Lo, Antoni Ribas, Richard Marais
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
Douglas J. Schwartzentruber, David H. Lawson, Jon Richards, Robert M. Conry, Donald M. Miller, Jonathan Treisman, Fawaz Gailani, Lee B. Riley, Kevin C. Conlon, Barbara A. Pockaj, Kari Kendra, Richard L. White, René González, Timothy M. Kuzel, Brendan D. Curti, Phillip D. Leming, Eric D. Whitman, Jai Balkissoon, Douglas S. Reintgen, Howard L. Kaufman, Francesco M. Marincola, Maria J. Merino, Steven A. Rosenberg, Peter L. Choyke, Don Vena, Patrick Hwu
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis